ALKEM LABORATORIES

Making Positive Difference To Lives Across The Globe

Vision

To achieve value driven leadership in

Indian Health Care Industry and
beyond through

“Quality that is infinite”

“Service that cares”
“Hardwork that endures”.
Goal

To be one of the
Top 3 Companies
in India
and
also be a successful global
Company through
innovations and strategic alliances
Visionary Founder and Chairman
Managing Director
4 Decades Of Giant Strides

The Pharma Major since 1973…

Turnover Rs 1,293 cr

Ranked No. 5 in the Indian Pharma Industry

Enjoys high respect from Medical profession & trade in India

Reputed for building mega brands

4 Decades Of Giant Strides

Buoyant organic growth due to excellent marketing and sales

On the path of rapid globalisation

Products exported to 60 countries

… moving ahead to become one of the top 3 Indian companies

Sales Break Up
Acute And Chronic Segments

7%
Chronic
Segment

93%
Acute Segment
Total Sales Turnover

 Year 2005-06 2006-07 2007-08 2008-09 2009-10

Total Sales 169 226 239 272 318

Val in Mn US$
2009 - 10 Domestic Sales

SBU’s Value(in Crs)

Main Division 692.95

Bergen 150.91
Ulticare 95.73
Pentacare 13.79
Generic 111.08
Cytomed 21.72
Mediva 27.75

Derma Care 15.05

Alkem Pharma 29.70
Alkem Health Foods 6.82
Alkem Institution 6.34
Exports 121
Total (App.) 1293
Top 10 Domestic Company

 1. CIPLA
 2. RANBAXY
 3. GLAXO SMITHKLINE
 4. ZYDUS CADILLA
 5. NICHOLAS PIRAMAL
 6. SUN
 7. PFIZER
 8. ALKEM
 9. MANKIND
 10. LUPIN
Growth Rate of Company

 Mankind – 37%
 Pfizer – 33%
 Sun – 26%
 ALKEM – 23%
 Zydus Cadila – 23%
 Aristo – 20%
 Cipla - 18 %
 Glaxo Group - 17%
 Lupin - 16%
 Ranbaxy - 11%
ALKEM -A Brand Building Company

Taxim (Cefotaxime) – a flagship brand is among the top 15 brands

of Indian Pharmaceutical Industry

11 other brands in the list of top 300 mega brands

No. 1 in Cephalosporins

Front runners in Co-AmoxyClav and Quinolone segments

Brands In Top 300 Of
Indian Pharma Market
Rank Val in Cr.
Taxim (Cefotaxime) 11 131.72
Taxim-O (Cefixime) 15 105.88
Clavam (Co-Amoxyclav) 30 87.27
Pan 74 57.63
Sumo ( NSAID) 82 51.94
Gemcal (Calcitrol) 83 51.89
A TO Z (Multi Vitamin/Anti-oxidants) 94 45.53
Xone (Ceftriaxone) 117 40.82
Pan - D 145 36.84
Ondem 168 32.92
Hemfer (Hematinic) 232 27.29

ORG Mat May 2010

ALKEM in Cephalosporins

Value
Company Rank % MS % Gr
(in Cr.)
Market 3185.96 17
ALKEM 1 396.85 12.5 7

Aristo 2 271.72 8.5 25

Ranbaxy 3 246.63 7.7 17

ORG Mat May 2010

ALKEM in Co-AmoxyClav

Value
Company Rank % MS % Gr
(in Cr.)

Market 634.07 35

Glaxo Smithkline 1 154.21 24.43 31

ALKEM 2 93.95 14.8 33

Mankind 3 70.27 11 20

ORG Mat May 2010

ALKEM in Quinolones

Value
Company Rank % MS % Gr.
(in Cr.)

Market 972.71 4

Ranbaxy 1 191.26 19.7 14

Cipla 2 146.58 15.11 7

Mankind 3 72.02 7.4 14

ALKEM 8 31.61 3.2 26

ORG Mat May 2010

Firsts From Alkem

First Indian Company To Develop, Manufacture & Market

These Products In India

• Anaestrazole
• Cefotaxime + Sulbactam
• Satranidazole
• Ceftriaxone + Tazobactam
• Cefixime + Clavulanic Acid

First Company To Market These Products In India

• MEROPENAM
• CEFEPIME
Important New
Products Launched

• Cefixime + Clavulanic Acid

• Cefprozil
• Ceftriaxone + Tazobactam
• Gatifloxacin
• Pantaprazole + Itopride
• Cefpodoxime Proxetil
• Aceclofenac Range
• Rabeprazole
• Rabeprazole + Diclofenac
• Rabeprazole + Domperidone
• Meropenam
• Sodium Feredetate
• Cefipime
• Donepezil
• Piperacillin + Tazobactam

• Cefotaxime + Sulbactam
Important New
Products Launched
• Atorvastatin + Ezetemibe
• Pioglitazone + Metformin
• Metformin SR
• Glimepiride
• EsCitalopram
• Mirtazapine
• Quetiapine
• Nebivolol
• Levo Cetirizine
• Aripiprazole
• Bicalutamide
• Natural Micronised
Progesterone
• Anaestrazole
• Paclitaxel
NATURAL PRODUCTS
• Pycnogenol
INTERESTING NUTRACEUTICAL
PRODUCTS
• Protein Diskettes
• Meal Replacer Bars
• Nutraceutical soups
Our Core Strengths

Focussed SBUs

Technical Expertise

People

Logistics

Finance
Focussed SBUS
Focused SBU’s

Main Pharma Division

Ulticare

Bergen

Pentacare

Mediva

Cytomed

Derma Care
Therapy Representation Of SBU’s

Main Pharma
Ulticare
• Anti-infective • Anti-infective
• Nutraceuticals
• Gastroenterology • Anti-tuberculosis
• Special Focus - Paediatrics
• Gynecology

• Pediatric
Bergen
• Surgery • Anti‑infective
• Orthopedics
• Nutraceuticals • Nutraceuticals
• Dermatology
• Nsaids

• Urology
Therapy Representation Of SBU’s

Pentacare Mediva
• Cardio Vascular & Anti
• Anti‑parkinson's Diabetic Range

• Anti-depressants
• Anti-psychotics
• Anxiolytics
• Anti-epileptics
Cytomed
• Anti-cancer
• Anti retrovirals
Dermacare
Skin Care Division

• Anti‑alzheimer's
Diversified Business

Alkem Health Foods :

• Jeevan prash – a tasty, Low Calorie & sugar free chyawanprash

• Blocal – Low Calorie Sweetner

• Tammy :

• Salt Substitute, Fat Substitutes and Sucralose based products –

Jams, Cookies, Jelly, Juices & cakes (Calorie Conscious and
Diabetics), Cholesterol free edible Oil.
Technical Expertise
The Research And Development Centre
Active In Almost All Facets Of The Business

 R&D centre at Mumbai approved by DSIR

 Formulation development for domestic market

 Formulation development for MAA/ANDA program

 Process development group for APIs and nutraceuticals

 Fully equipped modern state-of-the-art labs

 Sophisticated information services

State-of-the Art Manufacturing Committed
To International Quality Compliance

 7 World class manufacturing facilities

 2000 Million units of Tablets per annum

 200 Million units of Capsules p.a

 500 Million units of Injectable p.a

 60 Million units of Liquids p.a

 600 Million units of dry syrups p.a

 30 Mn Units of I.V. infusions p.a.

Manufacturing Locations

 Daman – Amailya and Kachigam Plant

 Gujrat -Mandava and Ankaleshwar Plant

 Himachal Pradesh – Baddi

 Sikkim - Rangpo
Contract Research Organization
( Phoenix Bio-Pharma Research Centre )

 Conforming to International standards

 Bio- equivalence studies
 Drug Metabolism Pharmacokinetics
 Method Development / Method Validation etc.
 Post Marketing Surveillance
 Independent Ethics Committee comprising of well known
personalities eg. Dr. H.P. Tipnis
 Low cost for studies as compared to the west
People
ALKEM – Our People

Over 6000 employees

 Cohesive team of professionals with a proven track record and
complementary skills

 Well Trained, Competent and Dedicated field force across the country

 Creative & Vibrant strategic Marketing Team with experience of

building mega brands

 Competent pool of Scientists, Pharmacists & Technologists

Our Values

 Honesty and Integrity

 Respect/care & concern for people
 Customer Orientation
 Commitment to Quality
 Learning Organization
 Dedication and Commitment
 Trust
 Teamwork
 Openness and Transparency
 Discipline
 Result Oriented
Logistics
Selling & Distribution Channels

• Depots: 24
• C&F: 4
• Warehouse : 4
• 3000 Field Force spanning the entire country
• 1,40,000 retailer coverage
• 3,65,000 Doctor coverage ( 40 % of universe )
Finance
Financial Strength

 Negligible Debt; Major Project Cost and Expansion Programs met

out of Retained Earnings

 Low Borrowing Cost, Interest Cost progressively becoming nil, Net

Income generated on the Interest Front

 Owns substantial Properties and Tangible Assets

 Tax Planning, Profit Tax free subject to MAT

 Liquidity
 Accumulated Cash Reserves and Surplus
 Surplus available for Expansion, R&D and M&A Activity
International Footprint
Key Attributes

Excellent growth in exports in last 3 years

 
Currently exports to more than 60 countries

Exports to regulated markets in Europe including UK

Strategic Approach

1.   Marketing through agent network in Unregulated and

Semiregulated markets

2.  Regulated Markets

Toll manufacture for large generic companies in Highly regulated

markets like Europe, South Africa, Australia & USA

Own European filings & US ANDA’s

Strategic Alliances , Acquisitions & JV’s

Strategic Alliance

Contract manufacturing for generic companies in

regulated European Market

Alliance with other European and American generic

major`s in process

Tie-up for innovative nutraceuticals and food products in

process
REGULATORY APPROVALS

Cephalosporin Block – Oral & Injectable (Daman)

 Approved by UK MHRA ( orals & injectable )
 Approved by MCC, south Africa ( orals & injectable )
 Approved by ANVISA, brazil (injectable)

 Beta lactam block (daman)

 Approved by ANVISA brazil (injectables )
 Successfully inspected by UKMHRA ( Oral & Injectable)
– approval expected shortly

General block facility (daman)

 Approved by USFDA & UKMHRA( ORAL ) and also approved by ANVISA Brazil

USFDA Process for all the three Blocks has been initialized and
completed
Our New Ventures
Sucralose

Developed a cost effective , environment friendly,

patent non infringing process

Confirms to USP-NF specifications

Certified by CFTRI & BAJAJ centre

Dedicated facility based on regulated market requirements

Capacity : 10 tonnes/month
Foray Into Biotechnology

First Phase : HUMAN INSULIN

EPO
GCSF
INTERFERO
(GERMAN ASSOCIATION)
Looking Ahead…

 MAAs in European Market

 ANDAs in USA
 Contract manufacturing for generic companies in regulated European
Market
 In licensing arrangement for marketing PATENTED molecules in India
 Strategic alliances, Acquisitions & JVs
 Backward integration to API manufacturing.
 cGMP lab & pilot plant; futuristic contract research business opportunities
 Identifying and Contract research business opportunities
Why you should work with Alkem

 We are Growing organization

 Fast Career Growth

 Performance Driven Organization.

 We are growing at the rate of 23 % per annum as compared to the Industry

growth rate of 17 %.

 Compare to all top rank companies in domestic we are growing at higher rate.

 Incentive driven compensation structure.

 Believe in Fun at work place.

Web Site

 www. alkemlabs.com